Os Therapies Inc

This management proposal asks shareholders to approve an amendment and restatement of the company’s 2023 Incentive Compensation Plan primarily to (i) increase the share reserve by 5,000,000 shares (bringing the total initial reserve to 15,000,000), (ii) remove the Existing Plan’s per-person award caps, and (iii) update plan provisions to reflect recent U.S. federal tax law changes. Management seeks shareholder approval because stockholder consent is required for the issuance of additional shares under the plan and for certain tax-qualified treatment; the board frames the change as necessary to attract, retain and motivate executives, employees, directors and consultants by enabling competitive equity- and performance-based awards. The proposal sits in the context of prior increases to the plan reserve (from 2,000,000 to 4,000,000 and then to 10,000,000) and the stated remaining availability under the Existing Plan (1,575,463 shares as of the record date), which management says is insufficient for future hiring and incentivization needs. The board justifies eliminating per-person limits to provide the Compensation Committee flexibility to grant larger, performance-linked awards when merited, but retains committee discretion to set individual limits as needed. Key governance and investor considerations include dilution risk from the added 5,000,000-share reserve and the removal of per-participant caps, which could enable very large awards to individual executives absent committee-imposed limits or clear disclosure practices. The Amended and Restated Plan includes standard features (ISOs, non-qualified options, SARs, restricted/deferred stock, performance awards, dividend equivalents, and change-in-control and acceleration provisions) and contemplates administration by the Compensation Committee with board oversight. The board recommends FOR the proposal on the rationale that equity-based incentives align management with stockholders and are necessary to compete for talent, while opponents would typically point to dilution and potential governance weakness from removing per-person limits; the committee’s retained discretion and the company’s disclosures about available shares and historical grants are material context for evaluating execution risk. Implementation would increase the pool of shares available for long-term compensation, increasing potential dilution and compensation expense, and investors should weigh that against the expected benefits of improved recruiting, retention and performance incentives.